Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods
Authors:
- Kim L. CreditoKCKim L. Credito
- Mayuree KhantipongMKMayuree Khantipong
- Michael R. JacobsMJMichael R. Jacobs
- Peter C. AppelbaumPAPeter C. Appelbaum
Open Access
- 1 May 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 45 (5) , 633-638
Abstract
Chequerboard titrations were used to test the activity of trovafloxacin, alone and in combination with clindamycin or metronidazole, against 156 Gram-positive or Gram-negative anaerobes, including 47 Bacteroides fragilis group, 36 Prevotella spp., 26 fusobacteria, 21 peptostreptococci and 26 clostridia. MIC50/MIC90 values (mg/L) of each drug alone against all 156 strains were: trovafloxacin, 0.5/1; clindamycin, 0.25/2; metronidazole, 1/2. Synergy (FIC indices ≤ 0.5) was seen in two strains with trovafloxacin plus clindamycin, and seven with trovafloxacin plus metronidazole. All other combinations were additive (FIC indices >0.5–2.0); no antagonism (FIC indices >4.0) was seen. In addition, synergy was tested by time–kill methodology for each of the above combinations against 12 Gram-positive or Gram-negative strains. Results indicated that synergy (defined as a ≥ 2 log10 decrease in cfu/mL at 48 h compared with the more active drug alone) was found between trovafloxacin at or below the MIC and both clindamycin and metronidazole at or below the MIC in one strain each of Bacteroides fragilis, Bacteroides thetaiotaomicron, Prevotella intermedia, Fusobacterium varium, Peptostreptococcus asaccharolyticus and Clostridium bifermentans. Synergy between trovafloxacin (≤MIC) and metronidazole alone was seen in one strain each of Bacteroides distasonis, Prevotella bivia, Fusobacterium mortiferum, P. asaccharolyticus and C. bifermentans. In many cases of synergy, including those at the trovafloxacin MIC, regrowth after 48 h, which was commonly seen with trovafloxacin alone, was inhibited, and 99.9% killing was observed with the combination after 48 h, but not with trovafloxacin alone.Keywords
This publication has 19 references indexed in Scilit:
- Synergistic Activity of Trovafloxacin with Other Agents Against Gram-positive and -negative OrganismsDiagnostic Microbiology and Infectious Disease, 1998
- Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.Journal of Antimicrobial Chemotherapy, 1997
- Comparison of Activities of Trovafloxacin (CP-99,219) and Five Other Agents Against 585 Anaerobes with Use of Three MediaClinical Infectious Diseases, 1996
- The in-vitro activity of CP 99, 219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agentsJournal of Antimicrobial Chemotherapy, 1995
- In vitro activity of the new fluoroquinolone CP-99,219Antimicrobial Agents and Chemotherapy, 1994
- Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobesAntimicrobial Agents and Chemotherapy, 1994
- Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactamJournal of Antimicrobial Chemotherapy, 1993
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneAntimicrobial Agents and Chemotherapy, 1993
- In vitro activity of CP-74667 compared with four other fluoroquinolonesDiagnostic Microbiology and Infectious Disease, 1992